Radiopharm Theranostics reports durable partial response in Phase 1 RAD204 trial

The company said the confirmed response was seen in an ongoing early-stage study of RAD204 in patients with advanced solid tumors after immunotherapy.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.